Pro medicus plunges but analysts see prescription for a comeback amid market malaise
The gist
Despite a dramatic 56-60% share price plunge, Pro Medicus is defying market gloom with robust financials and bullish analyst forecasts that hint at a comeback.
What to know
- Shares have cratered nearly 60% in the past year, even as Pro Medicus locked in $280 million in new contracts and held EBIT margins above 70%.
- Analysts remain staunchly optimistic, with average price targets near $197 and highs up to $241.89—implying potential gains of 61% to almost 90%.
- Market-wide fears of AI disruption and growth stock fatigue have battered Pro Medicus and peers like Xero, but strong HY26 revenue growth and renewed contracts suggest value may be hiding in the wreckage.
Disconnect Between Results and Price
Pro Medicus’s sharp share price collapse stands in stark contrast to its surging contracts and elite profit margins, spotlighting a market skepticism that defies the company’s operational strength.
Despite Pro Medicus securing $280 million in new contracts and maintaining a robust client base of hospitals, imaging centres, and healthcare groups, its shares have plummeted by approximately 56-60% over the past year. This stark decline underscores a puzzling disconnect between the company's strong financial fundamentals and its market valuation, raising questions about whether the stock is oversold or facing broader market headwinds.
Pro Medicus’s ability to sustain exceptionally high EBIT margins above 70% positions it well for significant net profit growth, which has underpinned optimistic analyst price targets. If the company continues to win new customers and renew contracts on improved terms, this financial strength could justify a rebound in share price, suggesting the current market dip may present a long-term value opportunity rather than a value trap.
Margin Power Fuels Rebound Case
Sustained EBIT margins above 70% and a growing hospital client base position Pro Medicus for a potential earnings surge, making its current valuation look increasingly out of step with its financial trajectory.
Sustained EBIT margins above 70% and a growing hospital client base position Pro Medicus for a potential earnings surge, making its current valuation look increasingly out of step with its financial trajectory.
Analysts Bet on a Sharp Recovery
With seven out of eight analysts rating Pro Medicus a buy and projecting up to 90% upside, bullish forecasts are underpinned by record contract wins and expectations for double-digit earnings growth.
Despite Pro Medicus shares having fallen approximately 50-60%, analyst sentiment remains robustly optimistic, with major firms like Morgan Stanley and Bell Potter assigning price targets of $210 and $226 respectively, implying upside potential of 64% to 76% from current levels. This confidence is echoed broadly, as seven out of eight recent ratings classify the stock as a 'buy,' with an average price target near $197 suggesting a 61% gain over the next year, while the highest target of $241.89 hints at the possibility of the share price nearly doubling within 12 months.
Analyst optimism is firmly grounded in Pro Medicus’s strong financial performance and significant contract wins, which bolster expectations for sustained earnings growth. The company reported HY26 revenue of $124.8 million, a 28.4% year-on-year increase, alongside a 29.7% rise in underlying profit before tax to $90.7 million and an impressive EBIT margin exceeding 70%. Recent major contracts, including a 5-year $23 million deal with the University of Maryland Medical System, a 5-year $37 million renewal with Northwestern Medicine, and a 7-year $90 million agreement with Beth Israel Lahey Health, underpin confidence in the company’s growth trajectory and justify the bullish price targets.
While market concerns about AI disruption persist, analysts project strong earnings momentum for Pro Medicus, forecasting a 35.8% year-over-year EPS growth in FY27 to $1.863, up from $1.372 in FY26. This anticipated surge in profitability, supported by the company’s ability to secure new customers and renew contracts on favorable terms while maintaining a high operating margin, reinforces the rationale behind the positive price targets and the view that the stock represents a compelling value opportunity amid broader growth stock rotation.
Consensus among analysts, as reflected in TradingView data, rates Pro Medicus shares as a strong buy with an average projected upside of approximately 47% over the next 12 months, further validating the stock’s potential for significant recovery. This widespread endorsement highlights that despite recent share price weakness, the company’s robust fundamentals and expanding contract portfolio continue to inspire confidence in its medium-term growth prospects.
Growth Sector Rout Masks Value
Pro Medicus and peers like Xero and Siteminder are swept up in a growth stock selloff, yet analyst targets signal these battered names may be hiding some of the ASX’s biggest comeback stories.
Pro Medicus and Xero Ltd exemplify the broader market rotation away from expensive ASX growth stocks, each enduring steep share price declines of around 50-52% despite robust financial performances. Pro Medicus trades near $128.25 after a nearly 50% drop, while Xero sits at $83.43, down about 52%, reflecting investor caution even as both companies report strong revenue growth and operational metrics. This juxtaposition highlights a market environment where solid fundamentals are currently overshadowed by sector-wide sentiment shifts.
Analyst optimism contrasts sharply with the share price weakness seen in Pro Medicus and Xero, with Morgan Stanley and Bell Potter assigning Pro Medicus price targets of $210 and $226 respectively, implying upside potential exceeding 60%. Similarly, Xero’s average analyst target near $121.78 suggests a 46% gain, underscoring a consensus that these beaten-down stocks may be undervalued. This analyst confidence supports the view that current valuations offer compelling entry points amid ongoing market volatility.
Beyond Pro Medicus and Xero, other ASX growth stocks like REA Group and Siteminder Ltd have also faced significant price corrections despite strong operational results and positive broker sentiment. REA Group’s shares are down about 35% over the past year, yet brokers maintain buy ratings with upside potential around 37%, while Siteminder stands out with an average analyst price target implying a remarkable 111% upside. Both Siteminder and Xero’s investments in AI-driven features parallel Pro Medicus’s market context, illustrating how innovation remains central to growth narratives despite investor caution.